Management of pregnancy in systemic lupus erythematosus
暂无分享,去创建一个
[1] F. Kirkham,et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[2] E. Herlenius,et al. Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block , 2005, The Journal of experimental medicine.
[3] D. Mevorach,et al. Prevention of complete heart block in children of mothers with anti-SSA/Ro and anti-SSB/La autoantibodies: detection and treatment of first-degree atrioventricular block , 2009, Current opinion in rheumatology.
[4] J. Salmon,et al. Heparin prevents antiphospholipid antibody–induced fetal loss by inhibiting complement activation , 2004, Nature Medicine.
[5] D. El‐Haieg,et al. Plasmapheresis and pregnancy outcome in patients with antiphospholipid syndrome , 2007, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[6] M. Vilardell‐Tarrés,et al. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. , 2002, Rheumatology.
[7] D. Wlody,et al. Hypertension in pregnancy. , 1992, The New England journal of medicine.
[8] Mimi Y. Kim,et al. Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. , 2010, Arthritis and rheumatism.
[9] Y. El‐Sayed,et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. , 2000, American journal of obstetrics and gynecology.
[10] J. Piette,et al. The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in systemic lupus erythematosus and/or the antiphospholipid syndrome. , 2006, Rheumatology.
[11] K. Takakuwa,et al. Prospective Studies of the Association Between Anticardiolipin Antibody and Outcome of Pregnancy , 1995, Obstetrics and gynecology.
[12] S. le Cessie,et al. Classical complement activation as a footprint for murine and human antiphospholipid antibody‐induced fetal loss , 2011, The Journal of pathology.
[13] S. Taler,et al. ASH Position Paper: Hypertension in Pregnancy , 2009, Journal of clinical hypertension.
[14] W. Frishman,et al. Beta-adrenergic receptor blockers. Adverse effects and drug interactions. , 1988, Hypertension.
[15] F. Perlík. [Adverse effects and drug interactions]. , 2004, Casopis lekaru ceskych.
[16] A. Piccoli,et al. Steroid hormones and disease activity during pregnancy in systemic lupus erythematosus. , 2002, Arthritis and rheumatism.
[17] S. Bewley,et al. Pregnancy Outcomes in Systemic Lupus Erythematosus with and without Previous Nephritis , 2011, The Journal of Rheumatology.
[18] M. Cheung,et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. , 2010, Rheumatology.
[19] J. Craig,et al. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. , 2005, The Cochrane database of systematic reviews.
[20] L. Tam,et al. Predictors of maternal and fetal outcomes in pregnancies of patients with systemic lupus erythematosus , 2011, Lupus.
[21] Mimi Y. Kim,et al. Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. , 2009, Arthritis and rheumatism.
[22] G. Girardi. Role of Tissue Factor in the Maternal Immunological Attack of the Embryo in the Antiphospholipid Syndrome , 2010, Clinical reviews in allergy & immunology.
[23] K. Kalunian,et al. Assessing disease activity in SLE patients during pregnancy , 1999, Lupus.
[24] L. Magder,et al. The impact of increased lupus activity on obstetric outcomes. , 2005, Arthritis and rheumatism.
[25] C. Vasconcelos,et al. Pregnancy and Systemic Lupus Erythematosus: Review of Clinical Features and Outcome of 51 Pregnancies at a Single Institution , 2010, Clinical reviews in allergy & immunology.
[26] G. Koren,et al. Use of warfarin during pregnancy. , 2002, Canadian family physician Medecin de famille canadien.
[27] L. Hornberger,et al. Spectrum of Cardiac Involvement in Neonatal Lupus , 2010, Scandinavian journal of immunology.
[28] D. Marcelli,et al. Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[29] J. Hirsh,et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[30] K. Kuczkowski. Clopidogrel and pregnancy: a situation pregnant with danger? , 2009, Archives of Gynecology and Obstetrics.
[31] A. Ferrante,et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. , 2003, Arthritis and rheumatism.
[32] Mimi Y. Kim,et al. Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. , 2009, The American journal of cardiology.
[33] A. Einarson,et al. Use of diuretics during pregnancy. , 2009, Canadian family physician Medecin de famille canadien.
[34] J. Piette,et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients , 2008, Annals of the rheumatic diseases.
[35] S. Sonesson. Diagnosing Foetal Atrioventricular Heart Blocks , 2010, Scandinavian journal of immunology.
[36] Y. Shoenfeld,et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.
[37] M. Shaarawy,et al. Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling. , 2006, Contraception.
[38] Mimi Y. Kim,et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine , 2010, Annals of the rheumatic diseases.
[39] J. Atkinson,et al. Mutations in Complement Regulatory Proteins Predispose to Preeclampsia: A Genetic Analysis of the PROMISSE Cohort , 2011, PLoS medicine.
[40] P. Stoutenbeek,et al. Treatment of fetal heart block with maternal steroid therapy: case report and review of the literature , 2004, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[41] F. Di Nicuolo,et al. Pathogenic role of anti-beta2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin. , 2007, Human reproduction update.
[42] J. Salmon,et al. Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation. , 2008, Journal of reproductive immunology.
[43] L. Trupin,et al. Brief index of lupus damage: A patient‐reported measure of damage in systemic lupus erythematosus , 2011, Arthritis care & research.
[44] D. Gladman,et al. The Effect of Lupus Nephritis on Pregnancy Outcome and Fetal and Maternal Complications , 2010, The Journal of Rheumatology.
[45] D. Friedman,et al. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. , 1999, Arthritis and rheumatism.
[46] M. Petri,et al. Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. , 2008, The Journal of rheumatology.
[47] M. Petri,et al. Hopkins Lupus Pregnancy Center: 1987 to 1996. , 1997, Rheumatic diseases clinics of North America.
[48] E. L. Chia,et al. Cardiac time intervals of normal fetuses using noninvasive fetal electrocardiography , 2005, Prenatal diagnosis.
[49] Aeilko H. Zwinderman,et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis , 2008, Canadian Medical Association Journal.
[50] F. Schmidt. Meta-Analysis , 2008 .
[51] P. Maccallum,et al. Antenatal screening for pre-eclampsia: Evaluation of the NICE and pre-eclampsia community guidelines , 2012, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.
[52] Abdulrahman Al-Nabti,et al. Drug-eluting stent implantation for acute myocardial infarction during pregnancy with use of glycoprotein IIb/IIIa inhibitor, aspirin and clopidogrel. , 2008, The Journal of invasive cardiology.
[53] W. Weston,et al. Cutaneous lupus erythematosus during the neonatal and childhood periods , 1997, Lupus.
[54] M. Petri,et al. Disassociation of sex hormone levels and cytokine production in SLE patients , 2001, Lupus.
[55] C. Kimmel,et al. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment , 2003, Pharmacoepidemiology and drug safety.
[56] L. Hornberger,et al. Increased risk of complete congenital heart block in infants born to women with hypothyroidism and anti-Ro and/or anti-La antibodies. , 2006, The Journal of rheumatology.
[57] I. Stathopoulos,et al. The use of bisphosphonates in women prior to or during pregnancy and lactation. , 2011, Hormones.
[58] D. Friedman,et al. Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside , 2009, Nature Clinical Practice Rheumatology.
[59] E. Myers,et al. A national study of the complications of lupus in pregnancy. , 2008, American journal of obstetrics and gynecology.
[60] C. Laskin,et al. Decrease in pregnancy loss rates in patients with systemic lupus erythematosus over a 40-year period. , 2005, The Journal of rheumatology.
[61] B. Tura,et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study , 2001, Lupus.
[62] M. Petri,et al. Effect of pregnancy on serum cytokines in SLE patients , 2012, Arthritis Research & Therapy.
[63] A Tincani,et al. Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study. , 2010, Arthritis and rheumatism.
[64] E. Chakravarty,et al. Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. , 2006, Arthritis and rheumatism.
[65] P. Bossuyt,et al. Accuracy of Circulating Placental Growth Factor, Vascular Endothelial Growth Factor, Soluble fms-like Tyrosine Kinase-1, and Soluble Endoglin in the Prediction of Preeclampsia: A Systematic Review and Meta-Analysis , 2013 .
[66] Mimi Y. Kim,et al. Combined oral contraceptives in women with systemic lupus erythematosus. , 2005, The New England journal of medicine.
[67] M. Genovese,et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. , 2005, American journal of obstetrics and gynecology.
[68] L. Magder,et al. Thyroid disease in pregnant women with systemic lupus erythematosus: increased preterm delivery , 2011, Lupus.
[69] J. Buyon,et al. Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry. , 2000, The Journal of pediatrics.
[70] E. Makrakis,et al. Low‐molecular‐weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome , 2009, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[71] C. Gordon,et al. Measuring systemic lupus erythematosus activity during pregnancy: validation of the lupus activity index in pregnancy scale. , 2004, Arthritis and rheumatism.
[72] I. Bruce,et al. SLE and pregnancy: the potential role for regulatory T cells , 2011, Nature Reviews Rheumatology.
[73] C. Gordon,et al. Anti-inflammatory and immunosuppressive drugs and reproduction , 2006, Arthritis research & therapy.
[74] Kent R Bailey,et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[75] L. Magder,et al. Early Risk Factors for Pregnancy Loss in Lupus , 2006, Obstetrics and gynecology.
[76] E. Jaeggi,et al. The Benefits of Transplacental Treatment of Isolated Congenital Complete Heart Block Associated with Maternal Anti‐Ro / SSA Antibodies: A Review , 2010, Scandinavian journal of immunology.
[77] R. Xu,et al. Birth outcomes in women who have taken leflunomide during pregnancy. , 2010, Arthritis and rheumatism.
[78] N. Field,et al. Pregnancy outcomes in women with systemic lupus erythematosus , 2001, The Journal of maternal-fetal medicine.
[79] S. Hernández-Díaz,et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. , 2006, The New England journal of medicine.
[80] D. Back,et al. A Longitudinal Study of Maternal Dose Response to Low Molecular Weight Heparin in Pregnancy , 2003, Obstetrics and gynecology.
[81] C. Ris-Stalpers,et al. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms‐like tyrosine kinase 1 and soluble endoglin in the prediction of pre‐eclampsia: a systematic review and meta‐analysis , 2012, BJOG : an international journal of obstetrics and gynaecology.
[82] I. Bruce,et al. Decreased live births in women with systemic lupus erythematosus , 2011, Arthritis care & research.
[83] Mimi Y Kim,et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. , 2010, Arthritis and rheumatism.
[84] L. Jara,et al. Impact of previous lupus nephritis on maternal and fetal outcomes during pregnancy , 2012, Clinical Rheumatology.
[85] C. Hom,et al. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases , 2009, Pediatric rheumatology online journal.
[86] G. Hughes,et al. Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. , 1996, British journal of rheumatology.
[87] K. Michaud,et al. Effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus , 2012, Arthritis care & research.
[88] H. Sørensen,et al. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study , 2001, BMJ : British Medical Journal.
[89] J. Smallhorn,et al. Transplacental Fetal Treatment Improves the Outcome of Prenatally Diagnosed Complete Atrioventricular Block Without Structural Heart Disease , 2004, Circulation.
[90] Lindheimer,et al. American Society of Hypertension. ASH Position Paper: Hypertension in Pregnancy , 2009 .
[91] A. Tincani,et al. Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study , 2002, Lupus.
[92] R. Xu,et al. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. , 2012, Arthritis and rheumatism.
[93] L. Magder,et al. The Clinical Utility of Measuring Complement and Anti-dsDNA Antibodies During Pregnancy in Patients with Systemic Lupus Erythematosus , 2011, The Journal of Rheumatology.
[94] J. Kingdom,et al. The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus a prospective study of 186 antibody-exposed fetuses and infants. , 2010, Journal of the American College of Cardiology.
[95] L. Magder,et al. Hydroxychloroquine in lupus pregnancy. , 2006, Arthritis and rheumatism.
[96] Mimi Y. Kim,et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. , 2012, Arthritis and rheumatism.
[97] Mimi Y. Kim,et al. Utility of Cardiac Monitoring in Fetuses at Risk for Congenital Heart Block: The PR Interval and Dexamethasone Evaluation (PRIDE) Prospective Study , 2008, Circulation.
[98] B. Hammond. Lupus , 2004 .
[99] M. Petri,et al. Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience. , 2010, Arthritis and rheumatism.
[100] Robert C. Wolpert,et al. A Review of the , 1985 .
[101] F. Petraglia,et al. High Levels of Maternal Serum IL‐17 and Activin A in Pregnant Women Affected by Systemic Lupus Erythematosus , 2011, American journal of reproductive immunology.
[102] G. Koren,et al. Nonsteroidal Antiinflammatory Drugs During Third Trimester and the Risk of Premature Closure of the Ductus Arteriosus: A Meta-Analysis , 2006, The Annals of pharmacotherapy.
[103] K. Hongo,et al. A case report and review of the literature , 2006, Journal of Neuro-Oncology.
[104] M. Petri,et al. Management of antiphospholipid syndrome in pregnancy. , 2006, Rheumatic diseases clinics of North America.
[105] J. Sánchez-Guerrero,et al. A trial of contraceptive methods in women with systemic lupus erythematosus. , 2005, The New England journal of medicine.
[106] E. Jaeggi,et al. Non‐Cardiac Manifestations of Neonatal Lupus Erythematosus , 2010, Scandinavian journal of immunology.
[107] D. Friedman,et al. Association of the idiotype:antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmune-associated congenital heart block. , 2011, Arthritis and rheumatism.
[108] M. Petri. The Hopkins Lupus Pregnancy Center: ten key issues in management. , 2007, Rheumatic diseases clinics of North America.
[109] L. Trupin,et al. Contraceptive counseling and use among women with systemic lupus erythematosus: A gap in health care quality? , 2010, Arthritis care & research.
[110] J. Douketis,et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. , 2011, The Canadian journal of cardiology.
[111] P. Meroni,et al. Anti-phospholipid antibody mediated fetal loss: still an open question from a pathogenic point of view , 2010, Lupus.
[112] D. Mevorach,et al. Early Diagnosis and Treatment of Atrioventricular Block in the Fetus Exposed to Maternal Anti-SSA/Ro-SSB/La Antibodies: A Prospective, Observational, Fetal Kinetocardiogram–Based Study , 2009, Circulation.
[113] M. Petri. Prospective study of systemic lupus erythematosus pregnancies , 2004, Lupus.
[114] R. Kaaja,et al. Prevention of recurrence of congenital heart block with intravenous immunoglobulin and corticosteroid therapy: comment on the editorial by Buyon et al. , 2003, Arthritis and rheumatism.
[115] C. Gordon,et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. , 2008, Rheumatology.
[116] D. Balaban,et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. , 1992, American journal of obstetrics and gynecology.
[117] K. Bailey,et al. Maternal and foetal outcomes in pregnant patients with active lupus nephritis , 2009, Lupus.